Core Viewpoint - Galapagos NV has completed the works council consultation process and will proceed with the wind-down of its cell therapy activities, impacting approximately 365 employees across multiple locations [1][2]. Group 1: Wind-Down Announcement - The decision to wind down cell therapy activities follows a strategic review and exploration of divestment options, with consultations in Belgium and the Netherlands now concluded [1][2]. - The wind-down will lead to the closure of sites in Leiden (Netherlands), Basel (Switzerland), Princeton and Pittsburgh (U.S.), and Shanghai (China) [2]. Group 2: Future Strategy - Post wind-down, Galapagos aims to reposition itself for long-term growth through transformative business development, maintaining operations at its headquarters in Mechelen, Belgium, and hubs in Chicago and San Francisco [3]. - The company will continue to manage non-cell therapy activities, including the TYK2 program GLPG3667, and will evaluate strategic alternatives for further development in severe auto-immune indications [3]. Group 3: Financial Position - As of December 31, 2025, Galapagos reported approximately €3.0 billion in cash and cash equivalents, and financial investments [4]. - The company plans to provide updates on the estimated timeline and costs associated with the wind-down during its full year 2025 earnings release on February 23, 2026 [4].